Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

AI & computational technology for improving drug discovery & development — mati gill, CEO, AION labs.

Mati Gill is the Chief Executive Officer, of AION Labs (https://aionlabs.com/), a company recently launched and backed by a coalition of pharma and tech leaders, including AstraZeneca, Merck, Pfizer, Teva, Amazon Web Services (AWS), and the Israel Biotech Fund (IBF) and Israel Innovation Authority, to improve the whole drug discovery & drug development process with AI and computational biology.

Mati has an MBA (Healthcare & Innovation) and BS degree in law from Reichman University / IDC Herzliya, and has over a decade of experience in leadership roles in the biopharma industry, including most recently as Head of Government Affairs, Corporate & International Markets, at Teva Pharmaceuticals.

Mati also spent 4 years as Member Of The Board Of Advisors and Directors, at Sanara Ventures, a healthcare investment platform backed by Philips & Teva, providing Pre-seed, Seed and A round financing to young companies.

Prior to teva, mati was chief of staff to israel’s minister of public security.

Read more | >

A drug used to treat agitation in people with dementia is no more effective than a placebo, and might even increase mortality, according to a new study. A drug used to treat agitation in people with dementia is no more effective than a placebo, and might even increase mortality, according to a ne.

Read more | >

𝙎𝙘𝙞𝙚𝙣𝙩𝙞𝙨𝙩𝙨 𝙂𝙧𝙤𝙬 “𝙢𝙞𝙣𝙞 𝙗𝙧𝙖𝙞𝙣𝙨” 𝙞𝙣 𝙩𝙝𝙚 𝙇𝙖𝙗-𝙁𝙞𝙣𝙙 𝙋𝙤𝙩𝙚𝙣𝙩𝙞𝙖𝙡 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩 𝙋𝙖𝙩𝙝 𝙛𝙤𝙧 𝙁𝙖𝙩𝙖𝙡 𝙉𝙚𝙪𝙧𝙤𝙡𝙤𝙜𝙞𝙘𝙖𝙡 𝘿𝙞𝙨𝙚𝙖𝙨𝙚

Cambridge researchers have developed ‘mini brains’ that allow them to study a fatal and untreatable neurological disorder causing paralysis and dementia – and for the first time have been able to grow these for almost a year.

A common form of motor neuron disease, amyotrophic lateral sclerosis, often overlaps with frontotemporal dementia (ALS/FTD) and can affect younger peo… See More.

Read more | >

A team of researchers publishing in Aging have shown that resveratrol reduces inflammation and partially restores function in a rat model of spinal injury.

In line with previous research

This is far from the first study that aimed to use approaches associated with aging research in order to spur regeneration. For example, we have previously reported that removing senescent cells aids in spinal cord regeneration in a rodent model, at least partially because of the associated reduction in inflammation.

Read more | >

Circa 2020 o.o Basically a molecular printer could make your own vaccine for any disease.

Tesla Inc is building mobile molecule printers to help make the potential COVID-19 vaccine being developed by CureVac in Germany, the electric-car maker’s Chief Executive Officer, Elon Musk, tweeted on Wednesday.

Read more | >

Dr. Ann Marie Kimball (https://epi.washington.edu/faculty/kimball-ann-marie/) is a physician, epidemiologist and currently holds the roles of Associate Fellow at the international affairs think tank Chatham House, and Vice Chair, COVID 19 task force, at The Rotary Foundation / Rotary International.

Previously, Dr. Kimball served as a strategic advisor to the Rockefeller Foundation, supporting the strengthening and development of strategies for Ebola, post-Ebola, and health crisis response, including planning and guiding the formation of a regional disease surveillance network in collaboration with Connecting Organizations for Regional Disease Surveillance (CORDS).

Before joining the Rockefeller Foundation, Dr. Kimball served as technical and strategic lead for the Bill and Melinda Gates Foundation surveillance strategy formation.

Prior to Gates, Dr. Kimball served as Professor of Epidemiology for the University of Washington (UW), School of Public Health, with adjunct appointments in Medicine (Bioinformatics and Infectious Diseases) and the Jackson School of Foreign Affairs. During her tenure at UW, Dr. Kimball founded and directed the APEC Emerging Infections Network, and led research and training programs in Surveillance and Informatics in Peru and Thailand.

Dr. Kimball’s research focus on global trade and emerging infections earned her a Fulbright New Century Scholars award and a Guggenheim Scholars award.

Dr. Kimball is also the author of Risky Trade: Infectious Diseases in an Era of Global Trade, which was highly reviewed by NEJM, Emerging Infections and Lancet. She has authored numerous scientific publications, and served on numerous Institute of Medicine panels. She is also a fellow in the American College of Preventive Medicine and member of the National Biosurveillance Advisory group (NBAS) from the Centers for Disease Control.

Read more | >

Recent advancements in biotechnology have immense potential to help address many global problems; climate change, an aging society, food security, energy security, and infectious diseases.

Biotechnology is not to be confused with the closely related field of biosciences. While biosciences refer to all the sciences that study and understand life, biology, and biological organisms, biotechnology refers to the application of the knowledge of biosciences and other technologies to develop tech and commercial products. Biotechnology is the application of innovation to biosciences in a bid to solve real-world medical problems.

Throw Artificial Intelligence into the mix and we suddenly have a really interesting pot of broth. Several AI trends have already proven beneficial to the development of biotechnology. Dr. Nathan S. Bryan, an inventor, biochemist and professor, who made a name for himself as an innovator and pioneer in nitric oxide drug discovery, commercialization, and molecular medicine, offers his insights on these contributions.

Read more | >

This type of cell could lead to an unlimited cell division in human cells aka a forever lifespan 😃 #immortality

“The sequencing and posting of the HeLa genome brought into sharp relief important ethical and policy issues,” said Dr. Collins. “To understand the family’s perspectives, we met with them face to face three times over four months, and listened carefully to their concerns. Ultimately, we arrived at a path forward that respects their wishes and allows science to progress. We are indebted to the Lacks family for their generosity and thoughtfulness.”

The HeLa Genome Data Use Agreement

The new controlled access policy for full genome sequence data from HeLa cells will give the Lacks family the ability to have a role in work being done with the HeLa genome sequences and track any resulting discoveries. Under the policy, biomedical researchers who agree to abide by terms set forth in the HeLa Genome Data Use Agreement will be able to apply to NIH for access to the full genome sequence data from HeLa cells. Along with representatives from the medical, scientific, and bioethics communities, two representatives of the Lacks family will serve on NIH’s newly formed, six-member working group that will review proposals for access to the HeLa full genome sequence data. In addition, NIH-funded researchers who generate full genome sequence data from HeLa cells will be expected to deposit their data into a single database for future sharing through this process. The database study page will be accessible after the embargo lifts at this url: http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000640.v1.p1. Other investigators will be encouraged to respect the wishes of the family and do the same. Importantly, all researchers who use or generate full genomic data from HeLa cells will now be asked to include in their publications an acknowledgement and expression of gratitude to the Lacks family for their contributions.

Read more | >